Declared hepatitis C screening strategies in blood recipients in French hospitals.
OBJECTIVE
In spite of official recommendations and measures in France, screening strategies of hepatitis C performed in the field of transfusion are not clearly known. The aim of this study is to describe the screening strategies before and after the current year of the transfusion in blood recipients in several French medical departments and hospitals.


METHODS
A qualitative study using the key informant technique was carried out. A sample of 179 departments and 64 hospitals in charge of patients transfused with low or high-volumes of homologous blood products was constituted. The key informants were asked about the number of homologous blood products, the number of recipients transfused in the hospital, the volume of transfusion performed, the existence of a single defined screening strategy, the time of prescription of the biological tests (before or after transfusion), the tests performed on cryopreserved blood samples, and the indications of the transfusion.


RESULTS
The main screening strategy was HCV serology (second or third generation of enzyme immunoassays) with transaminase assessments before and after transfusion in 14% of the declared screening strategies. Screening tests were more frequently prescribed after transfusion, in at least 64% of the declared screening strategies according to the volume of transfusion. HCV serology was the common test prescribed in 61 and 50% of the screening strategies for low and high-volume transfusion respectively. The screening strategies showed a large heterogeneity combining HCV serology, transaminase assessment, before or after transfusion.


CONCLUSIONS
A great heterogeneity of screening strategies was found. The most frequent was HCV serology with transaminase assessment before and after transfusion. Recommendations on screening strategies are needed in order to limit practice heterogeneity. This study will help building a cost-efficacy model in order to guide public health decision making.
Jusot
J F
JF
Observatoire régional de la santé, PACA, INSERM U 379, 13006 Marseille, France.
Aubert
C
C
des Floris
M F Leconte
MF
Rotily
M
M
Lançon
F
F
Colin
C
C
Jullien
A M
AM
Fournel
J J
JJ
Laubriat
L
L
Fabre
G
G
Botté
C
C
Montcharmont
P
P
D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D005602:France / Q000453:epidemiology; D006526:Hepatitis C / Q000097:blood / Q000175:diagnosis* / Q000453:epidemiology / Q000635:transmission; D018937:Hepatitis C Antibodies / Q000097:blood; D006761:Hospitals; D006801:Humans; D007124:Immunoenzyme Techniques; D007297:Inpatients; D008111:Liver Function Tests; D008403:Mass Screening / Q000379:methods* / Q000706:statistics & numerical data; D012494:Sampling Studies; D012698:Serologic Tests / Q000379:methods; D011795:Surveys and Questionnaires; D065227:Transfusion Reaction
D018937:Hepatitis C Antibodies; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase